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1. Introduction 
We have shown that a soluble, low-molecular 
weight, alkali-labile and oxidation-sensitive factor, 
prepared from the electric organ of Torpedo ocellata, 
induces Cap-dependent acetylcholine (ACh) release 
from isolated Torpedo synaptic vesicles [ 1,2]. Diverse 
activities of ascorbic acid in the brain have been 
reported [3-81. These include effects on metabolism 
of biogenic amines [9] and on release of neurotrans- 
mitters from isolated mammalian vesicles [lo]. 
We therefore tested the possibility that ascorbic 
acid may be the soluble factor present in Torpedo 
and thus a naturally-occurring mediator of ACh 
release in vivo. 
2. Experimental 
2 .I . Preparation of synaptic vesicles and the soluble 
factor 
Crude (Pa) and purified (SV) synaptic vesicles 
were prepared as in [ 111. 
When the soluble factor was prepared, the electric 
organ was homogenized (15%, w/v) in 1 mM EGTA 
(pH 6.6) and centrifuged as in [ 11. The Ss fraction 
was passed through an Amicon PM-IO filter and the 
filtrate lyophilized and kept at -20°C up to several 
weeks. 
2.2. Preparation of synaptosomal cytoplasm 
The synaptosomal fraction a2 + a3 [ 12,13 3 (- 20 mg 
protein) was homogenized vigorously in water and 
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proteins were precipitated by trichloroacetic acid 
(5%, v/v). The clear extract served for both ascorbic 
acid determination and activity measurements (vide 
infra). In the latter case, extract obtained from 5 mg 
protein was used per ml reaction mixture. 
2.3. Measurement of AC% and A TP release 
This was carried out as in [ 111, except that the 
reaction was conducted in 30 mM Tris-HCI (pH 7.2) 
which contained KC1 (100 mM), NaCl(20 mM), 
EGTA (1 mM), dithiothreitol (DTT) (20 PM), glycine 
(480 mM), apyrase (0.25 mg/ml), and the designated 
concentrations of ascorbic acid or the Torpedo 
soluble fractions. The vesicles (2-4 nmol ACh/ml; 
0.6-l nmol ATP/ml) were preincubated with the 
buffer for 2 mm, after which release was induced by 
addition of CaC12. The concentration of free CaZc was 
calculated according to [ 141. 
2.4. Assays 
The vesicular ACh and ATP were assayed as in 
[15,16]. Ascorbic acid was determined by the micro- 
method of [17] on trichloroacetic acid-extracted frac- 
tions. Protein was determined according to [ 181. 
3. Results 
The electric organ of Torpedo ocellata was found 
to contain ascorbic acid (200 f 70 nmol/g tissue in 
the homogenate), 85-95% of which was recovered 
in the Ss fraction. The amount of ascorbic acid in S3 
was 20 f 6 nmol/mg protein. 
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Fig.1. Kinetic profiles of the effects of various concentrations of L-ascorbic acid on vesicular ACh (A) and vesicular ATP (B). 
Release from P, was induced by 50 PM Caz+ and the following L-ascorbic acid concentrations (PM): (e - l ) 0; (a - A) 0.2; (o - o) 
0.5 ; (0 - 0) 1 .O; (0 - 0) 5 .O. (* - l ) corresponds to 5 .O PM L-ascorbic acid and 50 NM Ca’* added to purified (SV) synaptic vesicles. 
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Fig.2. (A) Dose-response curves for the effect of Ca’* on the vesicular ACh (A) and ATP (0). The results shown were obtained 
15 min after stimulation with Ca** in the presence of 5 JAM L-ascorbic acid. (B) Dose-response curves for the effect of L-ascorbic 
acid on the vesicular ACh (A) and ATP (0). The results plotted were observed 15 min after stimulation with 50 PM Cal* (fig.1). 
The points shown are the mean t SD of > 4 expt for ACh and the mean f the range of 2 expt for ATP. 
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Low concentrations of L-ascorbic acid induced a 
gradual, Ca2+dependent and dose-relate& ’ crease in 
g both the vesicular ACh and ATP (flg.1). S’ e the 
purified (SV) and the crude (Ps) synaptic ves% 
were similarly affected by ascorbic acid (fig.l), t& 
latter were routinely used in subsequent experiment\s. 
~ Half-maximal effect of L-ascorbic acid was found at 
-1 PM (fig2B). The effect of various Ca” concentra- 
tions, in the presence of saturating Lascorbic acid 
levels (5 MM), is depicted in fig.2A. Half-maximal 
effects were observed at 3 PM Ca2+ (ACh release) and 
1 E.~M Ca2+ (ATP release). High concentrations of Ca2+ 
alone (< 1 mM) and of L-ascorbic acid alone (< 0.50 mM) 
were ineffective. Neither Mg2+ nor external ATP 
were required. Furthermore, external ATP (150 PM) 
completely inhibited the releasing effect of 5 PM 
L-ascorbic acid and 50 MM Cap. D-iso ascorbic acid 
also induced Ca2’dependent release, in concentra- 
tions comparable to those of L-ascorbic acid. NADH 
(0.5 mM) and glutathione (0.2 mM) were completely 
ineffective, suggesting that the effects of ascorbic 
acid are not due merely to its reducing capability. 
The subcellular origin of the ascorbic acid present 
in Ss is not known. We therefore examined the 
possibility that ascorbic acid may be present in the 
nerve terminal. The synaptosomal cytoplasm was 
indeed found to contain ascorbic acid (3 f 1 nmol/mg 
protein), and to induce a marked decrease in vesicular 
ACh (75% after 15 min). 
4. Discussion 
The finding that ascorbic acid is present in the 
electric organ and that it can induce a Ca2+dependent 
release of the vesicular contents suggests that ascorbic 
acid is the active component of the Torpedo soluble 
factor [ 1,221. This conclusion is supported by the 
following similarities between the soluble factor and 
ascorbic acid: low molecular weight; sensitivity to 
alkaline medium and oxidation; neither requires Mg” 
or ATP and both are inhibited by external ATP. In 
addition, preliminary findings show that they coelute 
on an ionexchange Dowex 1 -X2 column. 
Our results are similar to those in [lo], where ACh 
and noradrenaline release from ascorbic acid-treated, 
Ca”-stimulated rat brain synaptic vesicles was shown. 
It should be noted, however, that Mg2+ and ATP are 
essential for ACh release from rat brain synaptic 
vesicles by both rat brain synaptosomal cytoplasm 
[ 191 and ascorbic acid [lo]. This difference could 
mean that the molecular mechanisms involved in the 
release process from Torpedo and from mammalian 
synaptic vesicles are different. It is plausible that ATP 
present in Torpedo vesicles may serve as the energy 
source for the process. 
The concentration of ascorbic acid in the nerve 
terminal is not known. The specific concentrations 
of ACh and ascorbic acid in the nerve terminal are 
115 nmol/mg protein [ 13 ] and 3 nmol/mg protein, 
respectively. Assuming ACh at 20 mM in the nerve 
terminal [20], we obtain -0.5 mM ascorbic acid, 
implying that the presently reported in vitro effects 
of ascorbic acid may also occur in vivo. 
The physiological significance of the present 
finding is not yet known. It could be an in vitro mani- 
festation of the Ai?h release process which, in vivo, 
gains its vectorial character by interactions with the 
presynaptic membrane. Alternatively, ascorbic acid 
may be involved in maintaining the balance between 
the vesicular and the cytoplasmic pools of ACh 
within the nerve terminal. 
Acknowledgement 
This work was supported in part by the Israel 
Center for Psychobiology. 
References 
[II 
121 
131 
[41 
151 
;61 
(71 
Michaelson, D. M., Pinchasi, I. and Sokolovsky, M. 
(1978) Biochem. Biophys. Res. Commun.80,547-552. 
Michaelson, D. M., Pinchasi, I., Angel, I., Ophir, I., 
Sokolovsky, M. and Rudnick, G. (1979) in: Molecular 
Mechanisms of Biological Recognition. (Balaban, M. ed) 
pp. 361-372, Elsevier/NorthHolland, Amsterdam, 
New York. 
Sharma, O.P. and KrishnaMurti,C. R. (1976) J. Neuro- 
them. 27,299-301. 
Sharma, S. K., Johnston, R. M. and Quastel, J. H. 
(1963) Can. J. Biochem. Physiol. 41,597-604. 
Spector, R. and Lorenzo, A. V. (1974) Am. J. Physiol. 
226,1468-1473. 
Inagaki,C. (1970) Jap. J. Pharmac. 20,52-60. 
Glynn, I. M. (1963) J. Physiol. Lond. 169,452-465. 
191 
Volume 108, number 1 FEBS LETTERS December 1979 
[8] Matsuda, T., Maeda, S., Baba, A. and Iwata, H. (1979) 
J. Neurochem. 32,443-448. 
[9] Subramanian,N. (1977) Life Sci. 20,1479-1484. 
[lo] Kuo, C. H., Hata, F., Yoshida, H., Yamatodani, A. and 
Wada, H. (1979) Life Sci. 24,911-916. 
[ 1 l] Michaelson, D. M. and Ophir, I. (1979) in: Proc. 24th 
Oholo Conf. Neuroactive compounds and their cell 
receptors, ZichronYaakov, 1979,Karger, Basel, in press. 
[ 121 Michaelson, D. M. and Sokolovsky, M. (1976) Biochem. 
Biophys. Res. Commun. 73,25-31. 
(131 Michaelson, D. M. and Sokolovsky, M. (1978) J. Neuro- 
them. 30,217-230. 
[ 141 Porzhel, H., Caldwell, P. C. and Ruegg, J. C. (1964) 
Biochim. Biophys. Acta 79,581-591. 
[ 151 The Edinburgh Staff (1970) in: Pharmacological Experi- 
ments on Isolated Preparations (Livingstone E.; S., eds) 
London. 
[ 161 Holmsen, H., Holmsen, I. and Bernhardsen, A. (1966) 
Anal. Biochem. 17,456-473. 
[ 171 Zannoni, V., Lynch, M., Goldstein, S. and Sato, P. 
(1974) Biochem. Med. 11,41-48. 
[18] Lowry,O.H., Rosenbrough,N. J.,Farr,A. L.and 
Featherstone, K. (1961) J. Biol. Chem. 193,265-275. 
[ 191 Hata, F., Kuo, C. H., Matsuda, T. and Yoshida, H. 
(1976) J. Neurochem. 27,139-144. 
[20] Morel, M., Israel, M. and Manaranche, R. (1978) J. Neuro- 
them. 30,1553-1557. 
192 
